If You Invested $25,000 in Biogen in 2018, This Is How Much You Would Have Today

Five years ago, pharmaceutical manufacturer Biogen (NASDAQ: BIIB) had a growing business, and Tecfidera was its star multiple sclerosis treatment. Now, competition is

devastating the drug's sales, and without a replacement to make up for the decline, shares of Biogen have been falling as well. While all hope isn't lost in the business by

any means, it's been a volatile five years for investors, and I'll look at how much a $25,000 investment at the start of 2018 would be worth today, and whether you should consider

buying the stock now. Where Biogen's stock was five years ago On the first day of trading in 2018, shares of Biogen were $321.15 per share. Investing $25,000 into the

healthcare stock at the time would have allowed you to buy almost 78 shares. Last week, the stock finished at $288.04. At that price, those shares would now be worth about

$22,500, for a loss of 10% over that time. During that stretch, the S&P 500 has generated returns of nearly 50% without including dividends. Why has the stock performed so

poorly? Biogen's sales and profits struggled over the past five years. And without a dividend, there's not a whole lot of motivation for investors to buy shares of a business

that isn't growing. In 2017, Biogen's product revenue of $10.4 billion was up a modest 5.5% from the prior-year period. Top-selling multiple sclerosis drug

Tecfidera brought in $4.2 billion, up 6.2%.